G1 Therapeutics Inc. (GTHX)
NASDAQ: GTHX
· Real-Time Price · USD
7.16
0.01 (0.14%)
At close: Sep 17, 2024, 9:56 PM
G1 Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 16.55M | 14.48M | 14.87M | 12.3M | 42.39M | 12.95M | 10.25M | 23.58M | 10.57M | 6.9M | 5.8M | 4.86M | 6.6M | 14.22M |
Cost of Revenue | 733K | 1.08M | 1.26M | 3.08M | 1.4M | 1.46M | 992K | 1.11M | 976K | 669K | 374K | 591K | 808K | 243K |
Gross Profit | 15.81M | 13.4M | 13.62M | 9.22M | 40.99M | 11.49M | 9.26M | 22.46M | 9.6M | 6.23M | 5.42M | 4.27M | 5.8M | 13.97M |
Operating Income | -3.54M | -9.05M | -8.93M | -16.37M | 11.52M | -25.75M | -30.89M | -21.55M | -36.96M | -46.78M | -37.59M | -41.14M | -38.19M | -25.54M |
Interest Income | 225K | 281K | 529K | 585K | 643K | 716K | 478K | 211K | 50K | 9K | 8K | 7K | 9K | 19K |
Pretax Income | -5.47M | -10.22M | -9.98M | -17.3M | 10.02M | -27.59M | -33.17M | -24.05M | -39.45M | -49.19M | -39.77M | -42.15M | -39.2M | -26.3M |
Net Income | -5.47M | -10.22M | -10.88M | -18.2M | 8.71M | -32.53M | -33.65M | -25.27M | -41.93M | -51.6M | -40.02M | -42.47M | -39.42M | -26.44M |
Selling & General & Admin | 13.61M | 15.13M | 15.17M | 16.78M | 17.43M | 21.75M | 23.56M | 24.43M | 25.72M | 26.71M | 23.22M | 24.27M | 25.24M | 22.97M |
Research & Development | 5.74M | 7.32M | 7.38M | 8.81M | 12.04M | 15.48M | 16.59M | 19.58M | 20.84M | 26.3M | 19.79M | 21.14M | 18.75M | 16.54M |
Other Expenses | n/a | n/a | n/a | 3.08M | n/a | n/a | 237K | 48K | -127K | -155K | -138K | -76K | -92K | -40K |
Operating Expenses | 19.35M | 22.45M | 22.55M | 28.67M | 29.47M | 37.23M | 40.15M | 44.01M | 46.56M | 53.01M | 43.01M | 45.41M | 43.99M | 39.51M |
Interest Expense | 2.73M | 1.98M | 2.12M | 2.12M | 2.71M | 3.09M | 3M | 2.76M | 2.41M | 2.27M | 2.06M | 934K | 927K | 748K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.05M | n/a | n/a | n/a |
Cost & Expenses | 20.08M | 23.52M | 23.8M | 28.67M | 30.88M | 38.69M | 41.14M | 45.12M | 47.53M | 53.68M | 43.38M | 46M | 44.8M | 39.75M |
Income Tax Expense | n/a | 76.72K | 902K | 905K | 1.31M | 4.94M | 481K | 1.22M | 2.48M | 2.41M | 246K | 321K | 220K | 138K |
Shares Outstanding (Basic) | 52.48M | 52.17M | 51.84M | 51.78M | 51.67M | 51.65M | 46.28M | 42.8M | 42.71M | 42.69M | 42.41M | 42.38M | 42.12M | 40.7M |
Shares Outstanding (Diluted) | 52.48M | 52.17M | 51.84M | 51.78M | 61.04M | 51.65M | 46.28M | 42.8M | 42.71M | 42.69M | 42.54M | 42.38M | 42.12M | 40.7M |
EPS (Basic) | -0.1 | -0.2 | -0.21 | -0.35 | 0.17 | -0.63 | -0.73 | -0.59 | -0.98 | -1.21 | -0.94 | -1 | -0.94 | -0.65 |
EPS (Diluted) | -0.1 | -0.2 | -0.21 | -0.35 | 0.14 | -0.63 | -0.73 | -0.59 | -0.98 | -1.21 | -0.94 | -1 | -0.94 | -0.65 |
EBITDA | -2.62M | -8.93M | -8.8M | -15.06M | 12.86M | -24.37M | -30.04M | -21.15M | -36.9M | -46.81M | -37.47M | -41.1M | -38.16M | -25.44M |
EBIT | -2.74M | -8.24M | -7.85M | -15.18M | 12.73M | -24.51M | -30.17M | -21.29M | -37.04M | -46.93M | -37.72M | -41.21M | -38.27M | -25.56M |
Depreciation & Amortization | 121K | 120K | 124K | 127K | 130K | 132K | 137K | 139K | 139K | 115K | 114K | 117K | 118K | 120K |